Regulation of apoptosis by CD40 in B-cell lymphoma
Regulation of apoptosis by CD40 in B-cell lymphoma
CD40 is a cell surface signalling molecule expressed on normal B-cells and B-cells malignancies. Activations of CD40 (via binding CD40 ligand, CD40L) in normal B-cells promotes B-cell survival and is vital for activation of the immune response. However, activation of CD40 can induce or prevent apoptosis in malignant B-cells. Furthermore, CD40-activating agents are entering clinical trails as cancer therapies.
B-cells were isolated from over twenty Non-Hodgkin’s lymphomas and non-malignant lymph nodes and the effect of CD40 ligation on apoptosis and expression of apoptosis regulators was assessed. CD40L suppressed apoptosis in all B-cell malignancies tested, accompanied by significant increases in Bcl-XL protein expression and differential regulation of Bcl-X splicing and promoters. Mcl-1 protein expression was also regulated by CD40 stimulation. Although A20, survivin, Bfl-1 and BNIP3 (a novel CD40-target gene identified in this study) were regulated by CD40 in some samples, this was not consistent. Antisense oligonucleotides to Bcl-XL and Mcl-1 demonstrated that these proteins were key for survival of lymphoma cells. NF-κB mediated both the pro-survival effects of CD40 and upregulation of Bcl-XL and Mcl-1 expression. Microarrays were developed and used to characterise CD40-induced gene expression. This identified both novel CD40-target genes and also genes that were differentially regulated in cell lines with different survival outcomes to CD40 activation e.g. SLAM and SH2D1A.
Therefore, CD40 acts as a potent survival signal for primary B-cell lymphomas leading to regulation of the key anti-apoptotic proteins Bcl-XL and Mcl-1, via activation of NF-κB. This raises concerns over forthcoming clinical trails utilising CD40 activation as a treatment for cancer but suggests that targeting Bcl-XL, Mcl-1 or NF-κB may be a useful approach for treating lymphoma.
University of Southampton
Dallman, Claire Louise
754bbb8b-1a6b-41ee-83a8-d47adadf3acf
2003
Dallman, Claire Louise
754bbb8b-1a6b-41ee-83a8-d47adadf3acf
Dallman, Claire Louise
(2003)
Regulation of apoptosis by CD40 in B-cell lymphoma.
University of Southampton, Doctoral Thesis.
Record type:
Thesis
(Doctoral)
Abstract
CD40 is a cell surface signalling molecule expressed on normal B-cells and B-cells malignancies. Activations of CD40 (via binding CD40 ligand, CD40L) in normal B-cells promotes B-cell survival and is vital for activation of the immune response. However, activation of CD40 can induce or prevent apoptosis in malignant B-cells. Furthermore, CD40-activating agents are entering clinical trails as cancer therapies.
B-cells were isolated from over twenty Non-Hodgkin’s lymphomas and non-malignant lymph nodes and the effect of CD40 ligation on apoptosis and expression of apoptosis regulators was assessed. CD40L suppressed apoptosis in all B-cell malignancies tested, accompanied by significant increases in Bcl-XL protein expression and differential regulation of Bcl-X splicing and promoters. Mcl-1 protein expression was also regulated by CD40 stimulation. Although A20, survivin, Bfl-1 and BNIP3 (a novel CD40-target gene identified in this study) were regulated by CD40 in some samples, this was not consistent. Antisense oligonucleotides to Bcl-XL and Mcl-1 demonstrated that these proteins were key for survival of lymphoma cells. NF-κB mediated both the pro-survival effects of CD40 and upregulation of Bcl-XL and Mcl-1 expression. Microarrays were developed and used to characterise CD40-induced gene expression. This identified both novel CD40-target genes and also genes that were differentially regulated in cell lines with different survival outcomes to CD40 activation e.g. SLAM and SH2D1A.
Therefore, CD40 acts as a potent survival signal for primary B-cell lymphomas leading to regulation of the key anti-apoptotic proteins Bcl-XL and Mcl-1, via activation of NF-κB. This raises concerns over forthcoming clinical trails utilising CD40 activation as a treatment for cancer but suggests that targeting Bcl-XL, Mcl-1 or NF-κB may be a useful approach for treating lymphoma.
Text
927918.pdf
- Version of Record
More information
Published date: 2003
Identifiers
Local EPrints ID: 465219
URI: http://eprints.soton.ac.uk/id/eprint/465219
PURE UUID: 8d7bb5e5-1e49-4827-b626-10d9643c4800
Catalogue record
Date deposited: 05 Jul 2022 00:29
Last modified: 16 Mar 2024 20:02
Export record
Contributors
Author:
Claire Louise Dallman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics